Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02706392
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:00.517040+00:00
Published At
2022-08-31T00:00:00+00:00
Record Updated At
2022-08-31
Results Posted At
2022-08-31
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7", "Unresectable Lung Non-Small Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-08-31"
protocolSection.identificationModule.nctId
"NCT02706392"
protocolSection.identificationModule.officialTitle
"Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-08-31"

Study condition terms

  • Hematopoietic and Lymphoid Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Metastatic Lung Non-Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Triple-Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Stage III Lung Non-Small Cell Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Lung Non-Small Cell Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Lung Non-Small Cell Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Lung Non-Small Cell Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Unresectable Lung Non-Small Cell Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.